Portage, Michigan, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) will participate in Citi’s 2024 Unplugged Medtech and Life Sciences Access Day on Thursday, February 29, 2024 at Citigroup Headquarters, New York, New York.
Glenn Boehnlein, Vice President, Chief Financial Officer and Jason Beach, Vice President, Investor Relations will represent the Company in a presentation scheduled for 1:45 p.m. Eastern Time.
A simultaneous webcast and replay of the Company’s presentation will be available on Stryker’s website at www.stryker.com. The webcast will be archived on the Investor Relations page of this site.
About Stryker
Stryker is a global leader in medical technologies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in MedSurg, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 130 million patients annually. More information is available at www.stryker.com.
Contacts
For investor inquiries please contact:
Jason Beach, Vice President, Investor Relations at 269-385-2600 or This email address is being protected from spambots. You need JavaScript enabled to view it.
For media inquiries please contact:
Yin Becker, Vice President, Chief Corporate Affairs Officer at 269-385-2600 or This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$393.50 |
Daily Change: | 3.01 0.77 |
Daily Volume: | 1,180,969 |
Market Cap: | US$150.010B |
January 06, 2025 November 19, 2024 November 14, 2024 October 29, 2024 September 20, 2024 |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load